Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy

European Journal of Immunology

Volumn 31, Issue 5, 2001, Pages 1351-1360

  Kovacs, Joseph A ^a,d   Vogel, Susan ^b   Metcalf, Julia A ^b   Baseler, Michael ^d   Stevens, Randy ^d   Adelsberger, Joseph ^d   Lempicki, Richard ^d   Hengel, Richard L ^b,c   Sereti, Irini ^b   Lambert, Laurie ^d   Dewar, Robin L ^d   Davey Jr , Richard T ^b   Walker, Robert E ^b,e   Falloon, Judith ^b   Polis, Michael A ^b   Masur, Henry ^a   Lane, H Clifford ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d Aviron ^*

^e MEDIMMUNE   (United States)

Author keywords

AIDS; Cytokine; HIV; Immunomodulator; T lymphocyte

Indexed keywords

ANTIRETROVIRUS AGENT; CD38 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; HLA DR ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ALPHA CHAIN; ANTIGEN EXPRESSION; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INTERMITTENT THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOLOGICAL PROCEDURES; IMMUNOTHERAPY; LYMPHOCYTE COUNT; MALE; MEMORY CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TACHYPHYLAXIS;

ADP-RIBOSYL CYCLASE; ADULT; ANTIGENS, CD; ANTIGENS, CD38; ANTIGENS, DIFFERENTIATION; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; FLOW CYTOMETRY; HIV INFECTIONS; HLA-DR ANTIGENS; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MALE; MEMBRANE GLYCOPROTEINS; NAD+ NUCLEOSIDASE; RECEPTORS, INTERLEUKIN-2; TACHYPHYLAXIS; TIME FACTORS;

EID: 0035019084     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4141(200105)31:5<1351::AID-IMMU1351>3.0.CO;2-9     Document Type: Article

References (22)

1. Smith, K. A., Interleukin-2: inception, impact, and implications. Science 1988. 240: 1169-1176.
2. Kovacs, J. A., Baseler, M., Dewar, R. J., Vogel, S., Davey, R. T., Jr., Falloon, J., Polis, M. A., Walker, R. E., Stevens, R., Salzman, N. P., Metcalf, J. A., Masur, H. and Lane, H. C., Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N. Engl. J. Med. 1995. 332: 567-575.
3. Kovacs, J. A., Vogel, S., Albert, J. M., Falloon, J., Davey, R. T., Jr., Walker, R. E., Polis, M. A., Spooner, K., Metcalf, J. A., Baseler, M., Fyfe, G. and Lane, H. C., Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 1996. 335: 1350-1356.
4. Davey, R. T., Jr., Chaitt, D. G., Piscitelli, S. C., Wells, M., Kovacs, J. A., Walker, R. E., Falloon, J., Polis, M. A., Metcalf, J. A., Masur, H., Fyfe, G. and Lane, H. C., Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J. Infect. Dis. 1997. 175: 781-789.
5. Carr, A., Emery, S., Lloyd, A., Hoy, J., Garsia, R., French, M., Stewart, G., Fyfe, G. and Cooper, D. A., Outpatient continuous intravenous interleukin-2 or subcuaneous, polyethylene glycolmodified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. J. Infect. Dis. 1998. 178: 992-999.
6. Jacobson, E. L., Pilaro, F. and Smith, K. A., Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc. Natl. Acad. Sci. USA 1996. 93: 10405-10410.
7. Khatri, V. P., Fehniger, T. A., Baiocchi, R. A., Yu, F., Shah, M. H., Schiller, D. S., Gould, M., Gazzinelli, R. T., Bernstein, Z. P. and Caligiuri, M. A., Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies. J. Clin. Invest. 1998. 101: 1373-1378.
8. Kovacs, J. A., Imamichi, H., Vogel, S., Metcalf, J. A., Dewar, R. L., Baseler, M., Stevens, R., Adelsberger, J., Lambert, L., Davey, R. T., Jr., Walker, R. E., Falloon, J., Polis, M. A., Masur, H. and Lane, H. C., Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasispecies expression. J. Infect. Dis. 2000. 182: 1063-1069.
9. Ruscetti, F. W. and Gallo, R. C., Human T-lymphocyte growth factor: regulation of growth and function of T lymphocytes. Blood 1981. 57: 379-394.
10. Van Parijs, L., Biuckians, A., Ibragimov, A., Alt, F. W., Willerford, D. M. and Abbas, A. K., Functional responses and apoptosis of CD25 (IL-2R alpha)-deficient T cells expressing a transgenic antigen receptor. J. Immunol. 1997. 158: 3738-3745.
11. Fehniger, T. A., Bluman, E. M., Porter, M. M., Mrózek, E., Cooper, M. A., VanDeusen, J. B., Frankel, S. R., Stock, W. and Caligiuri, M. A., Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J. Clin. Invest. 2000. 106: 117-124.
12. + T lymphocyte expansion. Clin. Immunol. 2001, in press.
13. Piscitelli, S. C., Forrest, A., Vogel, S., Chaitt, D., Metcalf, J., Stevens, R., Baseler, M., Davey, R. T. and Kovacs, J. A., Pharmacokinetic modeling of recombinant interleukin-2 in patients with human immunodeficiency virus infection. Clin. Pharmacol. Ther. 1998. 64: 492-498.
14. + T cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat. Med. 1997. 3: 533-540.
15. + subjects. J. Clin. Invest. 1997. 100: 2737-2743.
16. Unutmaz, D., Pileri, P. and Abrignani, S., Antigen-independent activation of naive and memory resting T cells by a cytokine combination. J. Exp. Med. 1994. 180: 1159-1164.
17. + immunoregulatory T cells is antigen nonspecific. J. Immunol. 2000. 164: 183-190.
18. + T cell determinations in persons with human immunodeficiency virus (HIV) infections. MMWR 1994. 43: 1-21.
19. McFarland, R. D., Douek, D. C., Koup, R. A. and Picker, L. J., Identification of a human recent thymic emigrant phenotype. Proc. Natl. Acad. Sci. USA 2000. 97: 4215-4220.
20. Roederer, M., Dubs, J. G., Anderson, M. T., Raju, P. A. and Herzenberg, L. A., CD8 naive T cell counts decrease progressively in HIV-infected adults. J. Clin. Invest. 1995. 95: 2061-2066.
21. Baseler, M. W., Stevens, R. A., Lambert, L. A. and Metcalf, J. A., Immune-logical evaluation of patients with human immunodeficiency virus infection. In Rose, N. R., De Macario, E. C., Folds, J. D., Lane, H. C. and Nakamura, R. M. (Eds.) Manual of clinical laboratory immunology, 5th edn., ASM Press, Washington, DC 1997, pp 764-772.
22. Davey, R. T., Jr., Bhat, N., Yoder, C., Chun, T. W., Metcalf, J. A., Dewar, R., Natarajan, V., Lempicki, R. A., Adelsberger, J. W., Miller, K. D., Kovacs, J. A., Polis, M. A., Walker, R. E., Falloon, J., Masur, H., Gee, D., Baseler, M., Dimitrov, D. S., Fauci, A. S. and Lane, H. C., HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HMRT) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. USA 1999. 96: 15109-15114.